Sources say the brands will be kept separate, but some consolidation is occurring at the corporate level.
Stephen Joffe, MD, has regained control of LASIKPlus laser centers.
The Actavis moniker will be maintained for select regions and product portfolios.
Shares doubled in price the first day of trading, jumping from $23 to $50.
The Irvine, CA-based company markets the Presbia Flexivue Microlens corneal inlay for the treatment of presbyopia.
The company cited market conditions as the reason for the pullback.
The meeting is set for February 24 at the FDA White Oak campus.
The new models are designed to provide customized vision based on the lifestyle needs of each cataract patient.
This makes it the first drug in the treatment armamentarium for the progressive vision-threatening condition that is so common among people suffering from diabetes.
Branded prescription pharmaceuticals experienced the steepest climb with a 14.8 percent increase.
Revenues are expected to total nearly $1.3 billion in 2020.
Concerns raised by FDA during recent inspections may lead to more regulatory actions.
Revenues are forecast to grow to more than $750 million by 2019.
Seven witnesses testified at the hearing of the House Energy and Commerce Committee’s Subcommittee on Health.
You are not currently logged in.
©2017 Market Scope
Lost your Password